Autologous cancer vaccine - Vaccinogen

Drug Profile

Autologous cancer vaccine - Vaccinogen

Alternative Names: Active specific immunotherapy - Vaccinogen; ASI - Vaccinogen; Autologous tumour cell vaccine - Vaccinogen; Colon cancer vaccine - Intracel; OncoVAX

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intracel Corporation
  • Developer Intracel Corporation; National Cancer Institute (USA); Vaccinogen
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer
  • No development reported Malignant melanoma; Renal cancer
  • Discontinued Ovarian cancer

Most Recent Events

  • 18 Aug 2017 Vaccinogen's autologous cancer vaccine is at phase II development stage for Colorectal cancer (Combination therapy, Adjuvant therapy) in Netherlands and USA (Intradermal) (Vaccinogen website, August 2017)
  • 18 Aug 2017 No recent reports on development identified - Phase-III for Colorectal cancer (Adjuvant therapy) in Netherlands (Intradermal)
  • 18 Aug 2017 Vaccinogen plans a clinical trial for Colorectal cancer (Combination therapy) (Vaccinogen website, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top